USA flag logo/image

An Official Website of the United States Government

Potent Vaccine Adjuvant Therapeutic

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93346
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI077229
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
IMMURX LLC
16 Cavendish Court LEBANON, NH -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Potent Vaccine Adjuvant Therapeutic
Agency: HHS
Contract: 1R43AI077229-01A2
Award Amount: $577,222.00
 

Abstract:

DESCRIPTION (provided by applicant): Protective immunity against chronic infectious diseases such as TB will almost certainly require the generation of potent cellular immunity. To that end, we have recently developed a proprietary form of immunization (co mbined TLR/CD40-agonist immunization) which elicits a T cell response exponentially greater than traditional vaccination methods, and produces potent protective T cell immune memory. The overall goal of these experiments is to develop a novel and potent va ccine platform for chronic infectious diseases, with a production cost and shelf life consistent with the needs of the third world. We therefore propose to produce and evaluate the generation and maintenance of protective cellular immunity following immuni zation with both protein-based and DNA-based combined TLR/CD40-agonist vaccine. Importantly we will evaluate these vaccines for their induction of protective immunity against aerosol challenge with TB. While CD40 agonists and TLR agonists have been used se parately in previous clinical settings, combining these agonists into a proprietary vaccine formulation is a novel, patented concept with no previous clinical exposure. Thus, the studies proposed below constitute an innovative vaccine platform with the pot ential for high impact as a prophylactic and/or therapeutic TB vaccine. PUBLIC HEALTH RELEVANCE: Project Narrative ImmuRx has developed a novel, patented vaccine platform capable of generating immunity 10 times greater than conventional vaccination methods . Preliminary data has shown this vaccine to be successful in protecting against both viral and bacterial infections and we will now examine how well the vaccine can protect against infection with TB, a representative of a globally significant chronic infe ctious disease. The results of these studies will lead to pre-IND studies in anticipation of clinical trials and subsequent commercialization to bring this powerful treatment to patients in need.

Principal Investigator:

Hillary D. White

Business Contact:

David E. Delucia
delucia@immurx.com
Small Business Information at Submission:

IMMURX LLC
IMMURX Inc. 16 Cavendish Court LEBANON, NH 03766

EIN/Tax ID: 183046987
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No